Lake Street Capital Cuts Ekso Bionics (NASDAQ:EKSO) Price Target to $2.00

Ekso Bionics (NASDAQ:EKSO) had its price target reduced by Lake Street Capital from $2.50 to $2.00 in a research report report published on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

Other research analysts also recently issued reports about the company. StockNews.com assumed coverage on Ekso Bionics in a research note on Saturday, October 26th. They set a “hold” rating on the stock. HC Wainwright dropped their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday.

Ekso Bionics Stock Down 8.2 %

EKSO stock opened at $0.86 on Tuesday. The firm has a 50-day simple moving average of $1.11 and a two-hundred day simple moving average of $1.15. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 1.77. Ekso Bionics has a one year low of $0.83 and a one year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. During the same period in the previous year, the company earned ($0.24) EPS. As a group, research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC boosted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.